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Since our knowledge on structure and function of messenger RNA (mRNA) has expanded
frommerely being an intermediate molecule between DNA and proteins to the notion that
RNA is a dynamic gene regulator that can be modified and edited, RNA has become
a focus of interest into developing novel therapeutic schemes. Therapeutic modulation
of RNA molecules by DNA- and RNA-based therapies has broadened the scope of
therapeutic targets in infectious diseases, cancer, neurodegenerative diseases and
most recently in cardiovascular diseases as well. Currently, antisense oligonucleotides
(ASO), small interfering RNAs (siRNAs), and microRNAs are the most widely applied
therapeutic strategies to target RNAmolecules and regulate gene expression and protein
production. However, a number of barriers have to be overcome including instability,
inadequate binding affinity and delivery to the tissues, immunogenicity, and off-target
toxicity in order for these agents to evolve into efficient drugs. As cardiovascular diseases
remain the leading cause of mortality worldwide, a large number of clinical trials are
under development investigating the safety and efficacy of RNA therapeutics in clinical
conditions such as familial hypercholesterolemia, diabetes mellitus, hypertriglyceridemia,
cardiac amyloidosis, and atrial fibrillation. In this review, we summarize the clinical trials
of RNA-targeting therapies in cardiovascular disease and critically discuss the advances,
the outcomes, the limitations and the future directions of RNA therapeutics in precision
transcriptomic medicine.
Keywords: cardiovascular precision medicine, RNA therapy, antisense oligonucleotides, ASO, silence interfering
RNA, siRNA, aptamer, microRNA
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death and disability in developed countries
despite advances in risk stratification strategies and treatment (Benjamin et al., 2017). Thus, the
need for developing novel therapeutic strategies remains a major challenge in cardiovascular
medicine. Several lines of evidence have expanded our understanding of RNA function beyond its
role as an intermediate molecule between DNA and proteins to a dynamic and versatile regulator
of gene expression (Kapranov et al., 2007; Mercer et al., 2009). Today, we know that RNA is
Laina et al. Cardiovascular Precision Medicine: RNA Therapeutics
edited (Stellos et al., 2016), modified (Stellos, 2017b), forms
secondary and tertiary structures (Cate, 2016) and undergoes a
tight, dynamic and in some cases reversible post-transcriptional
regulation by a plethora of RNA-binding proteins (Cate,
2016; Stellos et al., 2016; Stellos, 2017b). To this end, RNA-
targeting therapies are currently under clinical development
by biotechnology companies expanding the range of “drug-
able” targets. Small interfering RNAs (siRNAs) and microRNAs
(miRNAs), the endogenous regulators of gene silencing, have
been investigated as potential therapeutic agents. Synthetic
siRNAs are used to inhibit the expression of the mRNA target,
while miRNA-based therapeutics comprise miRNA inhibitors
and miRNA mimics that antagonize and mimic the function
of an endogenous miRNA, respectively. Synthetic antisense
oligonucleotides and aptamers, a new class of either short
DNA or RNA oligonucleotides, are also used to target the
RNA. To date, RNA-targeting therapies are already being
applied in various diseases including cancer (Moreno and Pego,
2014), infectious (Schluep et al., 2017), and neurodegenerative
diseases (Scoles et al., 2017) as well. Nevertheless, RNA-targeting
therapeutic modalities merit various chemical modifications
prior to achieving greater stability and specificity, improved
potency, and decreased toxicity (Kole et al., 2012; Wittrup and
Lieberman, 2015).
The therapeutic potential of RNA-targeting therapies in
the context of cardiovascular disease therapeutics is currently
explored in multiple clinical trials. This review focuses on two
approaches used to therapeutically target RNA, that is siRNA
and ASOs, and summarizes the clinical trials of RNA-targeting
therapies in cardiovascular diseases. Further, we critically discuss
the advances, the outcomes, the limitations and the future
directions of RNA therapeutics in precision transcriptomic
medicine.
MECHANISMS OF ACTION AND
CHEMICAL MODIFICATIONS OF DNA-
AND RNA-BASED THERAPIES TARGETING
RNA MOLECULES
Therapeutic targeting of RNA (“transcriptomic medicine”)
is currently based on two main approaches: single-stranded
antisense oligonucleotides (ASO) and double-stranded RNA-
mediated interference (RNAi). Below, we discuss themechanisms
of action of RNA-targeting therapies and chemical modifications
introduced to improve drug design.
Antisense Oligonucleotides (ASOs)
Antisense oligonucleotides comprise a promising class of
synthetic agents designed to modulate gene expression (Shen
and Corey, 2018). They are short, typically 20 base pairs (bp)
in length, single-stranded DNA based oligonucleotides which
inhibit protein translation by binding to the target mRNA in a
sequence-specific manner via Watson-Crick base-pairing (Shen
and Corey, 2018). Antisense oligonucleotides target various
classes of nucleic acids inside the cell (pre-mRNA, mRNA,
non-coding RNA). ASOs have been developed to exert various
mechanisms of action depending on the location of hybridization
and ASOs’ chemical properties (Chan et al., 2006). ASOs inhibit
protein production mainly through stimulation of RNAase H
activity, which in turn results in target mRNA degradation (ASO
“Gapmers”) (Crooke, 1999). ASOs can also induce alternative
splicing by preventing binding of splicing factors (Dominski and
Kole, 1993; Havens and Hastings, 2016), resulting in translational
arrest through ribosome attachment blocking (steric hindrance)
(Crooke, 1999; Figure 1).
Antisense oligonucleotides are subject to chemical
modifications that can be utilized to improve their
pharmacodynamic and pharmacokinetic properties (Crooke
et al., 2017). Obstacles that have to be overcome are: (i) instability
and degradation by nucleases, (ii) low cellular uptake and
poor delivery to the tissues, (iii) inadequate binding affinity
to target mRNA, and (iv) off-target effects and toxicity (Kole
et al., 2012). To this purpose, phosphorothioate (PS) linkages
between the nucleosides that form the backbone were introduced
in replacement to phosphodiester bond generating the first
generation ASOs (Crooke et al., 2017). Phoshodiester linkages
are hydrophilic and highly charged, thus vulnerable to rapid
degradation by nucleases. In contrast, PS linkages confer
increased stability against nucleases and improve serum protein
binding, thus facilitating tissue distribution and increasing ASOs
pharmacokinetic profile (Dowdy, 2017). Sub-optimal affinity
of the target mRNA leading to low potency was addressed
by second and third generation ASOs, where 2′-O-Methyl
(2′-OMe), 2′-O-methoxyethyl (2′-OMOE), and Locked Nucleic
Acids (LNAs) are the leading types of chemical modifications,
respectively (Wahlestedt et al., 2000). Collectively, chemical
modifications result in improved stability and selective binding,
thus enabling efficient delivery (Freier and Altmann, 1997).
Small Interfering RNAs (siRNAs)
RNA interference (RNAi) is a highly conserved natural process
present in most eukaryotic cells in which double-stranded (ds)
RNA molecules silence the post-transcriptional expression of
specific genes (Siomi and Siomi, 2009). Small interfering RNAs
(siRNAs) and microRNAs are small non-coding RNAs consisting
major mediators of the RNAi process. siRNAs have been used
as synthetic mediators of RNAi specifically designed to silence
the expression of target genes (Siomi and Siomi, 2009). Unlike
ASOs which are single-stranded oligodeoxynucleotides, siRNAs
are double-stranded RNAmolecules ranging in length from 19 to
25 bp. After they are exogenously transfected into the cell, either
in a short form or in the form of long dsRNA molecules, they
are further incorporated into the RNAi machinery (Siomi and
Siomi, 2009). Long dsRNAs, transfected in low concentrations
to prevent immune response through activation of the interferon
pathway are cleaved byDicer, a dsRNA-specific ribonuclease, into
21–25 nucleotide-long double-strand siRNAs with 2 nucleotides
in their 3′ overhang and 5′ phosphate groups. siRNAs are
then recognized by the Argonaute 2 (AGO2) and RNA-induced
silencing complex (RISC) and unwind into their single strand
components (Sledz et al., 2003; Liu et al., 2004; Meister,
2013). The sense strand is degraded and its complement
(antisense) strand binds with perfect complementarity to the
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FIGURE 1 | RNA therapeutics in action. (A) Antisense oligonucleotides (ASOs); short, synthetic, single-stranded oligodeoxynucleotides that modify protein expression
through the following mechanisms (Ai) Inhibition of protein production by antisense gapmers through activation of the ribonuclease RNAase H resulting in target
mRNA degradation; (Aii) Control of splicing by ASOs in alternative splicing. ASOs can modulate alternative splicing by preventing the binding of splicing factors (SF)
resulting in translational arrest through ribosome attachment blocking; (B) siRNAs. Double stranded (ds) RNA is processed by Dicer, a dsRNA-specific ribonuclease,
into 21–25 nucleotide-long ds siRNAs with 2 nucleotides in their 3′ overhang and 5′ phosphate groups. siRNAs are then recognized by the Argonaute 2 (AGO2) and
loaded into the RNA-induced silencing complex (RISC) and unwind into their single strand components. AGO2, which is a component of RISC, cleaves the sense
strand of siRNA and the antisense strand binds with perfect complementarity to the target mRNA resulting in target mRNA cleavage; (C) microRNAs. Induction or
inhibition of gene expression by microRNA mimics or inhibitors. (D) Aptamers. Aptamers are single-stranded DNA or RNA molecules selected through a large
oligonucleotide library, called SELEX, to bind a specific target with high selectivity and specificity. Common targets include small metal ion and organic molecules,
proteins, viruses, bacteria and whole cells. Target recognition and binding involve three dimensional, shape-dependent interactions as well as hydrophobic
interactions. Here is a schematic illustration of the aptamer Pegaptanib inhibiting the action of the target protein VEGF-165 by binding to its receptor VEGFR.
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target mRNA sequence which is cleaved by AGO2 and degraded
by exonucleases (Rand et al., 2005; Ozcan et al., 2015; Figure 1).
Specificity and off-target effects depend on the
complementarity between an siRNA and the target gene
(Jackson and Linsley, 2010). In fact, the off-target effect along
with efficacy, delivery issues, immune system activation, and
toxicity are challenges in siRNA therapeutic approach that have
hampered their development into drug agents. Despite the fact
that siRNAs are designed to silence specific targets, they could
also knock down unintended genes, either through imperfect
complementarity to non-targeted mRNAs or by entering the
endogenous miRNA machinery (Jackson and Linsley, 2010).
Poor delivery of siRNAs due to rapid degradation by circulating
nucleases or rapid renal excretion has been addressed by
introducing chemical modifications including PS modifications,
hydrophobic ligands and encapsulation in nano carriers, in
order to increase both protection and half-life enabling systemic
delivery (Sledz et al., 2003; Kaczmarek et al., 2017). Chemical
modifications have also been employed to inhibit innate immune
system activation and release of pro-inflammatory cytokines
induced by siRNAs through toll-like receptor signaling pathways
(Shen and Corey, 2018).
microRNAs (miRNAs)
MicroRNAs are endogenous small non-coding RNAs which
similarly to siRNAs regulate gene expression at a post-
transcriptional level, with the exception that are capable of
silencing multiple mRNAs and not one target like siRNAs
(Lam et al., 2015). miRNA maturation is a stepwise process
during which miRNA is first transcribed as primary miRNA
(pri-miRNA), which in turn is processed to a loop-structured
precursor miRNA (pre-miRNA) of ∼60- to 70 nucleotides (nt)
by Drosha enzyme. Dicer, another RNase, cleaves the pre-miRNA
yielding a miRNA duplex of ∼22-nt which forms with the RISC
a complex called miRISC. The complex is then unwinding and
the sense strand is discarded leaving the single-stranded miRNA
to bind to the mRNA target through partial complementary
base pairing, resulting in gene silencing through translation
suppression (Figure 1). Oligonucleotides that target miRNAs are
known as antagomiRs, which bind with high complementarity
to miRISC preventing the binding of the complex to the mRNA
target. Oligonucleotides can also be synthezised tomimicmiRNA
function, providing another strategy for drug development (Li
and Rana, 2014). ASOs targeting microRNA undergo chemical
modifications in order to improve their pharmacokinetic profile,
binding and resistance from nuclease cleavage (Rupaimoole
and Slack, 2017). To date only one miRNA therapeutic agent,
miravirsen which is an LNA-modified DNA phosphorothioate
ASO that inhibits miR-122, has been evaluated in a clinical trial
(NCT01200420) in patients with chronic hepatitis C, showing
prolonged dose-dependent decreased HCV RNA levels without
serious adverse events (SAE) (Janssen et al., 2013). Several
experimental studies are investigating the use of miRNAs as
therapeutic targets in atherosclerosis, coronary artery disease and
myocardial infarction and clinical trials in humans are expected
to test microRNAs either as antagomiRs or microRNA mimics
in cardiovascular disease (Obad et al., 2011; Rayner et al., 2011;
Bernardo et al., 2012).
Aptamers
Aptamers are a new class of agents used both for diagnostic
and therapeutic purposes. They are synthetic single-stranded
DNA or RNA molecules selected for binding to a specific
target through an iterative process called SELEX (systematic
evolution of ligands by exponential enrichment) (Zhou and
Rossi, 2017). Numerous aptamers have been generated to target
a wide range of molecules, including small metal ion and
organic molecules, proteins, viruses, bacteria and whole cells.
The ability to form three dimensional interactions with their
targets renders them comparable to monoclonal antibodies.
In fact, they are often termed as “chemical antibodies” as
they share functional capacities with monoclonal antibodies.
On the other hand, aptamers have smaller size, higher affinity
and selectivity as compared to monoclonal antibodies and
importantly they possess a more flexible structure being able
to bind to inaccessible targets for larger antibodies. Taken
together, given these advantages as well as that aptamers
can be synthesized in vitro and lack immunogenicity, these
agents consist an attractive alternative therapeutic strategy to
monoclonal antibodies (Zhou and Rossi, 2017). Moreover,
besides binding their cognate protein, aptamers also act as
antagonists efficiently inhibiting the function of a specific target.
The first aptamer approved by the FDA, Macugen, is a typical
aptamer antagonist (Figure 1). Macugen was designed to target
vascular endothelial growth factor (VEGF) for the treatment
of age-related macular degeneration (AMD), however did not
show superior therapeutic effect than VEGF-specific monoclonal
antibodies (Ng et al., 2006; Mousa and Mousa, 2010; Ferrara and
Adamis, 2016).
CLINICALLY APPLICABLE TARGETS IN
CARDIOVASCULAR DISEASE
Apolipoprotein B is an essential structural component of
all atherogenic lipoproteins, including low-density lipoprotein
cholesterol (LDL-C), responsible for LDL-C transport and
removal and a major determinant of cardiovascular risk (Crooke
and Geary, 2013).Mipomersen is a 20 nucleotide-long antisense
oligonucleotide targeting apolipoprotein B (ApoB) mRNA
indicated in homozygous familial hypercholesterolemia (HoFH)
exerting its action by binding to ApoB mRNA and inhibiting the
subsequent synthesis of the protein through RNase H activation.
The approval of mipomersen [Kynamro, Kastle Therapeutics]
by FDA has paved the way towards investigating other possible
targets using antisense technology in the field of CVD.
One of the most promising targets is proprotein convertase
subtilisin/kexin-9 (PCSK9), which is responsible for reduced
LDL receptor expression and uptake of LDL-C and transport
into hepatocytes, resulting in elevated LDL-C circulating levels.
Inclisiran is a long-acting RNAi therapeutic agent that inhibits
the protein synthesis of PCSK9 and has been evaluated in a
phase 2 randomized clinical trial showing promising results
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(Ray et al., 2017; Table 2). Apolipoprotein C3 (APOC-III) is
another target currently being evaluated in patients with familial
chylomicronemia syndrome. APOC-III exerts its atherogenic
action by attenuating lipolysis of triglyceride-rich lipoproteins
through lipoprotein lipase (LPL) inhibition that results in
increased circulating levels of very low density lipoproteins
and chylomicrons (Huff and Hegele, 2013). Increased levels of
APOC-III are found in patients with hypertriglyceridemia and
have been causally associated with metabolic syndrome and
insulin resistance (Baldi et al., 2013). On the contrary, carriers
of mutations disrupting APOC-III function presented 40% lower
risk for coronary heart disease compared to non-carriers (TG
and HDL Working Group of the Exome Sequencing Project
et al., 2014). To date, Volanesorsen is a second generation
antisense oligonucleotide that has been designed to target APOC-
III mRNA and is currently being evaluated in phase 3 clinical
trials in patients with familial chylomicronemia syndrome (The
APPROACH Study, The COMPASS Study) (Table 4).
Apolipoprotein(a) is an essential component of
lipoprotein(a) which has been identified as an independent
risk factor for cardiovascular disease and calcific aortic valve
stenosis (Danesh et al., 2000; Capoulade et al., 2015). The
atherogenic properties of Lp(a) are attributed to the LDL-like
particle and apo(a) components and to the latter’s homology
to plasminogen, as well as to its content of pro-inflammatory
oxidized phospholipids (OxPL) (Wiesner et al., 2013).
Genome-wide association studies have identified
angiopoietin-like 3 (ANGPT3) and angiopoetin-like 4
(ANGPT4) as potential cardiometabolic therapeutic targets to
reduce cardiovascular burden. Several lines of evidence support
a beneficial metabolic profile in patients with loss-of-function
genetic variants in the gene encoding ANGPTL3 and ANGPTL4
expressed as low levels of plasma LDL cholesterol, high-density
lipoprotein (HDL) cholesterol, triglycerides, and reduced insulin
resistance (Robciuc et al., 2013; Dewey et al., 2016). An ASO
to ANGPTL3 has been developed and recently investigated in
human volunteers in a phase 1 clinical trial (Graham et al., 2017;
Table 1).
Coagulation factors are currently being investigated as
potential therapeutic targets and anti-coagulant aptamers have
been designed and tested in patients with coronary artery
disease. REG1 is a two-component system: RB006 is a single-
stranded, nucleic acid aptamer and comprises the anticoagulant
component inhibiting IX factor (Rusconi et al., 2002). Its
action is reversed by the antidote component of the REG1,
RB007 that binds and neutralizes RB006. Phase 2 clinical trials
have evaluated the efficacy of REG1 in patients with stable
CAD or ACS undergoing percutaneous coronary intervention
(PCI) compared to unfractionate heparin, reporting a beneficial
bleeding profile along with reduced thrombotic complications
in patients receiving the aptamer nucleic acid agent (Cohen
et al., 2010; Povsic et al., 2014; Table 2). However, a subsequent
study comparing the efficacy between REG1 anticoagulation
system and bivalirudin in patients undergoing PCI in terms
of periprocedural ischemic complications and major bleeding
was terminated due to severe allergic reactions reported in
subjects receiving the RNA aptamer (Ganson et al., 2016;
Lincoff et al., 2016). Of note, REG1 was not associated with
reduced bleeding and ischemic events compared to bivalirudin
(Lincoff et al., 2016). ARC-1779 is a 39-nucleotide modified
DNA aptamer designed to target vonWillebrand factor (Gilbert
et al., 2007) assessed in phase 2 studies in patients, undergoing
carotid endarterectomy and patients with acute myocardial
infarction undergoing PCI, respectively. However, both trials
have been terminated (NCT00742612 and NCT00507338) due
to slower enrolment than expected and unfeasible mode of drug
administration, respectively. Similarly, NU172 is a 26-nucleotide
unmodified DNA aptamer targeting thrombin. Results from a
phase 1 study provide initial evidence that this agent could
achieve reversal of anticoagulation without the need of an
antidote. An open-label phase 2 clinical trial has been conducted
to evaluate the therapeutic efficacy of NU172 in patients
undergoing CABG (NCT00808964). Its outcome is currently
unknown.
Chemokine C-C motif-ligand 2 (CCL2) is a pro-
inflammatory cytokine involved in the development of insulin
resistance and macrophage infiltration and recent evidence
supports a role of CCL2 in diabetic nephropathy (Carr et al.,
1994). A CCL2 antagonizing L-RNA aptamer (Spiegelmer) was
found to improve renal function in experimental studies and
after confirming a safety profile in a phase 1 clinical trial in
humans, emapticappegol (NOX-E36) was evaluated in a phase 2a
study in patients with type 2 diabetes mellitus and albuminuria
(Table 2). Patients treated with emapticappegol presented a
trend toward reduced urinary albumin excretion and HbA1c,
suggesting a promising role of this CCL2 inhibitor in both kidney
disease and diabetes mellitus (Menne et al., 2017).
Elevated levels of C-reactive protein (CRP) are associated
with high cardiovascular risk (Strandberg and Tilvis, 2000) and
could consist a potential target in RNA precision medicine. ISIS-
CRPRx is an ASO complementary to the coding region of the
human CRP mRNA and in a phase 1 double-blind placebo-
controlled study was administered in healthy volunteers during
the acute-phase response to endotoxin challenge (Noveck et al.,
2014). Pre-treatment with ISIS-CRPRx attenuated the expected
endotoxin induced increase in CRP levels in a dose-dependent
manner. The antisense agent was well-tolerated in all doses tested
(Noveck et al., 2014). Subsequently, this second generation ASO
was assessed in a phase 2 clinical trial in patients with paroxysmal
atrial fibrillation and an implanted dual chamber permanent
pacemaker. The rationale of the clinical trial was based on the
association between atrial fibrillation (AF) and inflammation
and evidence supporting increased CRP levels as a risk for AF
development and perpetuation (Dernellis and Panaretou, 2004;
Marcus et al., 2010; Liu et al., 2011; Pena et al., 2012). However,
no reduction in AF burden was observed in patients treated
with ISIS-CRPRx despite substantial decrease in CRP levels
(Sugihara et al., 2015). The potential anti-inflammatory effect of
ISIS-CRPRx has also been explored in rheumatoid arthritis in
a phase 2 clinical trial showing a dose-dependent reduction of
high sensitivity CPR (hs-CRP) at 36 days. In specific, the group
receiving 400mg ISI-CRPRx demonstrated a decrease equal to
76.7% in hs-CRP compared with a 14.4% decrease in the placebo
group at 36 days which was lost by day 92 (Warren et al., 2015).
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Small interfering RNAs and ASOs have been developed for
the treatment of transthyretin (TTR) amyloidosis, a progressive
heart disease causing severe congestive heart failure. After
siRNAs encapsulated in lipid nanoparticles were shown to
successfully induce transthyretin knockdown in patients with
TTR amyloidosis in a phase 1 study (Coelho et al., 2013), a
subsequent phase 2 study evaluated patisiran as a potential
therapeutic strategy in TTR mediated familial amyloidotic
polyneuropathy (Suhr et al., 2015). The ENDEAVOUR study
was a phase 3 double-blind placebo-controlled clinical trial that
evaluated the safety and efficacy of revusiran in patients with
TTR mediated familial amyloidotic cardiomyopathy but was
withdrawn due to safety concerns (NCT02319005) (Table 4).
Furthermore, a specific TTR antisense oligonucleotide (IONIS-
TTR) was evaluated in an open label study examining
functional and structural cardiac parameters in patients with
either hereditary or wild type TTR amyloidosis. Overall, the
ASO was well-tolerated slowing down the progression of disease,
as expressed by reduced left ventricular wall thickness and left
ventricular mass, improved global systolic strain, 6-min walk test
and NYHA class (Benson et al., 2017).
RNA-TARGETING THERAPEUTICS IN
RANDOMIZED CLINICAL TRIALS
Apolipoprotein B
Mipomersen
The efficacy of subcutaneous administration of mipomersen at
200 mg/weekly dosage has been explored in phase 3 clinical trials.
In particular, Raal et al., reported a mean percentage reduction in
LDL-C levels, of∼25% (95% CI−31.6 to−17.7) in patients older
than 12 years old with homozygous FH already receiving the
maximum tolerated dose of a lipid-lowering drug, compared with
a ∼3% decrease in the placebo group. Twenty-six out of thirty-
four treated patients experienced injection-site reactions, and
four presented a significant increase in alanine aminotransferase
(Raal et al., 2010; Table 3).
Similar results were reported by McGowan et al., who
randomly assigned 58 patients with heterozygous FH and/or
coronary heart disease (CHD) to either placebo or s.c.
mipomersen 200 mg/weekly on top of the maximally tolerated
dose of lipid-lowering drugs. The mipomersen group presented
a 36% reduction of LDL-C from a baseline of 278 mg/dL
in comparison to the placebo group which presented a
13% reduction from a baseline of 250 mg/dL. Conventional
hypolipidemic drugs have limited effect on Lp(a). Surprisingly, in
this study mipomersen induced a significant reduction in Lp(a)
compared to placebo (−33 vs. −1.5%). Adverse events included
injection site reactions, alanine transaminase increase and flu
like symptoms (McGowan et al., 2012). Another study of similar
design and population, that is patients with heterozygous FH
and coronary artery disease, reported similar results concerning
percentage change of LDL-C up to week 28. In specific,
mipomersen decreased mean LDL-C by 28.0% compared with
5.2% increase with placebo. Moreover, mipomersen significantly
reduced apolipoprotein B (−26.3%), total cholesterol (−19.4%),
and Lp(a) (−21.1%) compared with placebo. No significant
change occurred in HDL-C. Adverse events included injection
site reactions and flu-like symptoms (Stein et al., 2012; Table 3).
The efficacy of mipomersen was also investigated in
hypercholesterolemic subjects of high cardiovascular risk. In
specific, 158 patients on maximally tolerated lipid lowering
agents statin and LDL-C>100 mg/dL were randomized into
receiving placebo (n = 53) or mipomersen (n = 105) for a
26-week period. Mean % change in LDL-C was −37% with
mipomersen vs. −5% with placebo. No changes in HDL-C were
observed, while on the contrary significant reductions were
established in apoB (38%), total cholesterol (26%) and Lp(a)
(24%) (Cromwell et al., 2012). Along this line, another study
evaluated the efficacy of mipomersen in patients with baseline
LDL cholesterol levels>100 mg/dL with or at high risk for CHD
already receiving maximally tolerated lipid-lowering therapy.
Mipomersen reduced LDL cholesterol by 36.9% compared to
placebo’s effect of 4.5%. Target LDL cholesterol <100 mg/dl was
achieved in 76% of mipomersen and 38% of placebo patients.
Mipomersen conferred significant reductions in other lipid
parameters as well. As in previous mipomersen studies, most
common adverse events included injection site reactions (78%
with mipomersen vs. 31% with placebo) and flu-like symptoms
(34% with mipomersen vs. 21% with placebo) (Thomas et al.,
2013; Table 3).
Finally, mipomersen was evaluated in high-risk patients with
statin intolerance. LDL cholesterol decreased by 47.3%, with a
parallel decrease in apoB by 46.2% and Lp(a) by 27.1%. Injection
site reactions and flu-like symptoms were the most common
adverse events resulting in 18% of the mipomersen-treated
patients and 17% of the placebo-treated patients discontinuation
of therapy. Among mipomersen treated patients, 33% of them
presented liver function tests above three times the upper limit of
normal (Visser et al., 2012; Table 3).
Interestingly, Duell et al. (2016) sought to assess the rate of
major adverse cardiovascular events (MACE) across a follow-
up period of 24 months in patients with FH having received
mipomersen for at least 12 months in a post-hoc analysis of three
RCTs and one open-label study (Santos et al., 2015). Patients
after mipomersen initiation treatment experienced 13 MACE
in comparison to 146 MACE identified in the 2-year period
previous to the mipomersen therapy. In fact, the authors report
that FH patients after mipomersen treatment initiation present
94.7% lower odds of experiencing MACE compared with the
pre-treatment period.
Apolipoprotein C-III
Volanesorsen
Volanesorsen is a second-generation 2′-O-methoxyethyl
chimeric ASO that is designed specifically to reduce levels of
APOC-III messenger RNA (mRNA). Through ribonuclease
H1, volanesorsen induces the degradation of the target mRNA
and inhibits the production of the APOC-III protein. This
glycoprotein plays a regulative role on lipoprotein metabolism
and single nucleotide polymorphisms (SNPs) in the APOC-III
gene are emerging as a cause of severe hypertriglyceridemia.
A recent meta-analysis found evidence that two SNPs in
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TABLE 4 | Ongoing clinical trials on RNA therapeutics in cardiovascular disease.
Trial registration
number
Status Study
design
Phase Condition (n) Intervention arm Comparator Estimated
completion date
PCSK9
NCT03060577
(ORION-3)
Active-not
recruiting
Open label 2 FH (n = 490) Inclisiran Evolocumab January 2022
NCT02963311
(ORION 2)
Recruiting Open-label 2 Homozygous FH (n = 10) ALN-PCS SOC December 2018
NCT03159416
(ORION-7)
Active, not
recruiting
Open-label 1 HCL and renal impairment (n = 24) Inclisiran September 2018
APOC-III
NCT02527343
(BROADEN Study)
Active, not
recruiting
RDBPC 2/3 Familial Partial Lipodystrophy (n = 60) Volanesorsen Placebo September 2021
NCT02900027 Recruiting RDBPC 1 Hypertriglyceridemia (n = 56) APOC-III-L-Rx Placebo September 2017
ANGPT3
NCT03371355 Recruiting RDBPC 2 Hypertriglyceridemia, Type 2 DM and NAFLD
(n = 144)
ISIS 703802 May 2019
NCT03455777 Not yet
recruiting
Open-Label 2 Homozygous FH (n = 3) ISIS 703802 December 2018
NCT03360747 Recruiting Open-Label 2 FCH (n = 3) ISIS 703802 September 2018
APO(a)
NCT03070782 Active, not
recruiting
RDBPC 2 Hyperlipoproteinemia(a) and CVD (n = 270) ISIS 681257 Placebo November 2018
GCGR
NCT02824003 Active, not
recruiting
RDBPC 2 Type 2 DM (n = 15) ISIS-GCGRRx Placebo May 2017
NCT02583919 Active, not
recruiting
RDBPC 2 Type 2 DM (n = 80) ISIS-GCGRRx Placebo March 2017
Completed trials with unpublished data
VEGF-A
NCT02935712 Completed RSBPC 1 CVD (n = 44) AZD8601 Placebo January 2018
APOC-III
NCT02211209
(APPROACH
Study)
Completed RDBPC 3 FCS (n = 67) Volanosersen Placebo March 2017
NCT02300233
(COMPASS Study)
Completed RDBPC 3 Hypertriglyceridemia (n = 114) Volanosersen Placebo January 2017
TTR
NCT02319005
(ENDEAVOR)
*Terminated RDBPC 3 Cardiac Amyloidosis (n = 206) ALN-TTRSC
(revusiran)
Placebo December 2017
*Due to an imbalance of mortality in the revusiran arm as compared to placebo. RDBPC, randomized double-blind placebo controlled; RSBPC, randomized single-blind placebo
controlled; PCSK9, proprotein convertase subtilisin/kexin type 9; FH, familial hypercholesterolemia; HCL, hypercholesterolemia; DM, diabetes mellitus; NFLD, non-alcoholic fatty liver
disease; CVD, cardiovascular disease; Apo(a), apolipoprotein a; ApoC-III, apolipoprotein C-III; ANGPTL3, angiopoietin-like 3; GCGR, glucagon receptor; FCS, familial chylomicronemia
syndrome; VEGF, vascular endothelial growth factor; TTR, transthyretin.
APOC-III are associated with increased CHD risk. In specific
two polymorphisms, SstI and T-455C, increased the odds
for CHD development by up to 48 and 77%, respectively
(Li et al., 2016).
In a phase 1 study, healthy volunteers received either
placebo (n = 8) or volanesorsen (ISIS 304801) (n = 25) and
presented a deep dose-dependent reduction up to ∼90%
and up to ∼80% of APOC-III and triglyceride levels,
respectively 4 weeks post-treatment (Graham et al., 2013;
Table 1). This led to a number of phase 2 clinical trials
investigating the effect of APOC-III inhibition in subjects with
hypertriglyceridemia.
Volanosersen was tested both as monotherapy and as
an adjunct to fibrates in a placebo-controlled RCT. When
administered as a single agent in fifty-seven subjects,
volanosersen resulted in a dose-dependent and prolonged
reduction in both plasma apoC-III (percentage decrease of
63.8 in the 200-mg group vs. an increase of 4.2% in the
placebo group) and triglyceride levels (−57.7% in the 200-mg
group vs. 20.1%). Similar results were observed when it was
administered as an add-on treatment to fibrates (Digenio
et al., 2016; Table 2). In addition, a phase 2 study explored the
effect of volanesorsen in subjects with hypertriglyceridemia
and poorly controlled type 2 diabetes. Volanosersen apart
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from significantly reducing apoC-III (−87.5% vs. −7.3%) and
triglyceride levels (−69 vs. −9.9%) compared to placebo, also
improved glycemic control, expressed as −0.44% reduction of
HbA1c at the end of follow-up, and increased insulin sensitivity.
Both findings were associated with suppression of apoC-III and
triglyceride levels (Bennet et al., 2008; Table 2). Yang et al., using
high-throughput ELISA to capture apoB, Lp(a) and apoA-I in
plasma, identified significantly reduced apoC-III levels on these
individual lipoproteins as apoCIII-apoB, apoCIII-Lp(a), and
apoCIII- apoAI complexes in subjects who received volanosersen
compared to those who received placebo (Yang X. et al., 2016;
Table 2).
Ongoing studies with volanesorsen include the APPROACH
[The APPROACH Study: A Study of Volanesorsen (Formerly
ISIS-APOCIIIRx) in Patients with Familial Chylomicronemia
Syndrome, NCT02211209] trial, the COMPASS [The COMPASS
Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx)
in Patients with Hypertriglyceridemia, NCT02300233] trial,
and the BROADEN [The BROADEN Study: A Study of
Volanesorsen (Formerly ISIS-APO-CIIIRx) in Patients with
Partial Lipodystrophy, NCT02527343] trial (Table 4).
PCSK9
Treatment with PCSK9 inhibitors, evolocumab and alirocumab,
reduce LDL-C levels by ∼60% (Desai et al., 2017). Interestingly,
the FOURIER (Further Cardiovascular Outcomes ResearchWith
PCSK9 Inhibition in Subjects With Elevated Risk) study has
shown additional cardiovascular benefit exerted by PCSK9
inhibition besides lipid lowering effect. Evolocumab significantly
reduced the risk of the composite endpoint of cardiovascular
death, myocardial infarction, stroke, hospitalization for unstable
angina, or coronary revascularization by 15% as compared to
placebo matched patients (HR 0.85, 95% CI 0.79–0.92) (Sabatine
et al., 2017). According to recently released results from meta-
analysis of 35 randomized controlled trials PCK9 inhibition
is not associated with improved all-cause (OR 0.71, 95% CI
0.47–1.09) or cardiovascular mortality (OR 1.01, 95% CI 0.85–
1.19). However, a metaregression analysis revealed an association
between higher baseline LDL-C and an all-causemortality benefit
(Karatasakis et al., 2017).
Inclisiran
Inclisiran (formerly known as ALN-PCS) is an investigational
GalNAc-conjugated siRNA targeting PCSK9, designed for
the treatment of hypercholesterolemia. Based on promising
preliminary results from phase 1 studies (Fitzgerald et al., 2014,
2016) in healthy volunteers (Table 1), the efficacy of inclisiran
was tested in a phase 2 double-blind, placebo-controlled RCT
in patients with history of CVD or CVD risk equivalents and
LDL levels over 70 or 100 mg/dl, respectively (Ray et al., 2017).
Patients were treated with the maximum tolerated dose of statins
before entering the study and were assigned to receive either a
single dose of placebo or inclisiran at doses 200, 300, or 500mg
or two doses of placebo/inclisiran at doses 100, 200, or 300mg
with a 3-month interval. The greatest reduction in LDL-C was
detected in the two-dose 300mg inclisiran group with nearly
half of the patients having an LDL cholesterol level below 50
mg/dL 6 months after treatment initiation. Importantly, both
PCSK9 and LDL cholesterol levels remained below the baseline
across a 8 months follow-up period (Table 2). The most common
adverse events (occurring in >2% of patients) included myalgia,
headache, fatigue, nasopharyngitis, back pain, hypertension,
diarrhea, and dizziness occurred among 11% of inclisiran treated
patients compared to 8% receiving placebo. Two deaths were
reported, one in a patient with CVD history assigned to the
single-dose 500-mg inclisiran group who experienced cardiac
arrest and the second in the single-dose 200-mg inclisiran group
who died from sepsis. Of note, injection site reaction and
transaminasemia were uncommon in inclisiran treated patients,
in contrast to high rates of these adverse events reported in
studies of ASOs described above.
Ongoing clinical trials are currently assessing the safety,
efficacy and tolerability of inclisiran under various different
clinical conditions. ORION-2 (NCT02963311) is a phase 2 open-
label clinical trial in patients with homozygous FH and ORION-
3 (NCT03060577) a phase 2, open-label, non-randomized,
extension trial designed to compare inclisiran to evolocumab
in high CVD risk patients (history of atherosclerotic CVD,
symptomatic atherosclerosis, type 2 DM or FH) with elevated
LDL cholesterol levels (Table 4).
SPC5001
Inhibition of PCSK9 was also assessed in a phase 1 double-blind,
placebo-controlled clinical trial using a 14-mer oligonucleotide
with locked nucleic acid (LNA) modifications, SPC5001 (van
Poelgeest et al., 2015). In total, twenty-three adult volunteers
withmild hypercholesterolemia (fasting LDL-C≥100mg/dl) were
enrolled, of whom 17 were exposed to Apo-B SNALP (Apo-
B siNA in an LNP formulation) and the rest to placebo. In
this first in-human study, SPC5001 reducedPCSK-9 by 49%.
Regarding lipid parameters, SPC5001 decreased LDL-C at the
end of therapy, but this effect was attenuated 3 weeks post
treatment. Importantly, dose-dependent injection site reactions
developed in 44% of the SPC5001-treated subjects and transient
serum creatinine increases of ≥20 µmol/L (15%) were observed.
Four out of six subjects receiving SPC5001 at the highest
dose developed renal tubular toxicity and one subject was
diagnosed with biopsy-proven acute tubular necrosis resulting
in termination of the clinical development of the study drug
(Table 1).
Lipoprotein(a)
Lipoprotein(a) is an independent risk factor for CVD events,
especially myocardial infarction (Waldeyer et al., 2017),
potentially through accelerated atherosclerosis as a result of
intimal deposition and/or prothrombotic or anti-fibrinolytic
effect as apolipoprotein (a) possesses structural homology
with plasminogen and plasmin. In a large prospective study
investigating the association between Lp(a) excess and incident
CHD reported an odds ratio of 1.60 (95% CI 1.38–1.85)
between the upper and lower thirds of baseline Lp(a) levels
after adjustment for traditional cardiovascular risk factors
(Bennet et al., 2008). Despite convincing data linking Lp(a)
with CVD, there is no definite clinical trial evaluating the effect
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of lowering Lp(a) on prevention of CHD. Currently, plasma
Lp(a) measurement, while not recommended for risk screening
in the general population, should be considered in people
with high CVD risk or a strong family history of premature
atherothrombotic disease (Nordestgaard et al., 2010).
An ASO targeting Lp(a) has been developed and tried in a
dose escalating phase 1 study conducted in healthy volunteers
with baseline levels of Lp(a)>250 nmol/L (100 mg/dL) (Table 1).
Patients assigned to treatment with ISIS-APO(a)Rx,received
single or multiple (six) subcutaneous injections ranging from 100
to 300mg over 4 weeks. No decrease in Lp(a) concentration was
observed in the single dose group, whereas patients receiving the
multiple dose scheme experienced a dose-dependent reduction in
Lp(a) levels (−39.6% in the 100mg group, −59% in the 200mg
group, and −77.8% in the 300mg group). The most common
adverse event was site injection reaction leading to treatment
discontinuation in one participant (Tsimikas et al., 2015). Two
randomized, placebo-controlled, dose ranging clinical trials were
subsequently conducted in order to investigate the efficacy,
safety, and tolerability of two unique ASOs -IONIS-APO(a)-LRx
and IONIS-APO(a)Rx- designed to lower Lp(a) concentrations
(Tables 1, 2). Significant reductions of Lp(a) between 62.8 and
84.5%were observed in the intervention arm compared to the
placebo group in both clinical trials. Concerning safety, both
ASOs were well-tolerated, although two episodes of myocardial
infarction were reported in the IONIS-APO(a)Rx phase 2 trial
that were deemed unrelated to the study drug (Viney et al., 2016).
Angiopoetin-Like Protein-3
Angiopoetin-like protein-3 has been established as a central
regulator of lipoproteinmetabolism and loss-of-function variants
have been associated with increased insulin sensitivity, reduced
free fatty acid circulating levels and decreased plasma lipid levels.
A study examining the relationship between ANGPTL3 loss-of-
function variants and coronary artery disease in 58,355 adults
reported that the presence of an ANGPTL3 loss-of-function
variant was associated with a 41% lower odds of CAD (OR
0.59; 95% CI 0.41–0.85) (Dewey et al., 2016). In a phase 1
RCT fourty-four volunteers (with triglyceride levels of either 90–
150mg per deciliter or >150mg per deciliter, depending on the
dose group) were randomly assigned to receive subcutaneous
injections of placebo or an ASO targeting ANGPTL3mRNA in a
single- or multiple doses scheme. Participants receiving the ASO,
presented dose-dependent reduction in ANGPT3 levels and
both lipids and lipoproteins. In specific, 6 weeks post-treatment,
the multiple-dose group presented reduced levels in reduced
ANGPTL3 protein (reduction of 46.6–84.5%) triglyceride levels
(reduction of 33.2–63.1%), LDL cholesterol (reduction between
1.3 and 32.9%), apolipoprotein B (reduction of 3.4–25.7%)
and apolipoprotein C-III (reduction of 18.9–58.8%) and these
reductions were significantly higher than those in the placebo
group. The agent was well tolerated with no serious adverse
events reported, or discontinuations of treatment (Graham
et al., 2017; Table 1). Safety and efficacy of ANGPTL3 is
now being explored in phase 2 clinical trials in subjects with
hypertriglyceridemia, type 2 diabetes mellitus and non-alcoholic
fatty liver disease (NCT03371355) and in patients with familial
chylomicronemia syndrome (NCT03360747) (Table 4).
FDA-APPROVED RNA THERAPEUTICS
Besides mipomersen, specific ASOs have received FDA approval
for use in non-cardiovascular diseases (Table 5). Fomiversen
[Vitravene, Novartis] is the first ASO to be approved for
clinical use in 1998 indicated for cytomegalovirus (CMV)
retinitis. This 21-mer phosphorothioate oligodeoxynucleotide
targets the mRNA encoding the CMV immediate-early (IE)-2
protein, which is required for viral replication (Vitravene Study
Group, 2002). Pegaptanib [Macugen, OSI pharmaceuticals,
Pfizer] is an aptamer targeting vascular endothelial growth
factor (VEGF165) and was approved by the FDA for the
treatment of AMD of the retina. This is the leading cause
of blindness in people older than 50 years of age and is
attributed to VEGF165-stimulated neovascularization of the
choroid (Gragoudas et al., 2004). Recently, approval was granted
for eteplirsen [Exondys 51, Sarepta Therapeutics] to be used in
Duchenne muscular dystrophy, a fatal neuromuscular disorder
characterized by a mutation in the dystrophin gene. Eteplirsen
exerts its action by restoring the translational reading frame
of dystrophin mRNA through specific skipping of exon 51
in the defective gene variants, thus promoting dystrophin
production (Mendell et al., 2013). Another FDA-approved ASO
is nusinersen [Spinraza, Biogen] a 18-mer phosphorothioate
2′-O-methoxyethoxy antisense oligonucleotide which modulates
alternative splicing of the survival motor neuron (SMN) gene and
is indicated for spinal muscular atrophy (Finkel et al., 2017).
CONCLUSION AND FUTURE
PERSPECTIVES
In conclusion, we are witnessing tremendous advances in
RNA therapeutics field and a rapid translation of experimental
studies to human clinical trials paving the way toward precision
medicine. There are challenges though to be overcome before
RNA-based therapeutic agents could efficiently evolve into drugs.
A number of chemical modifications have been introduced to
enhance target binding affinity, cellular uptake, pharmacokinetics
and drug potency along with the development of natural or
synthetic carriers to achieve efficient in vivo delivery (Wei
et al., 2017; Yin et al., 2017). Minimising off-target effects
and immunogenicity remains the most challenging setback and
significant efforts are being made in order to mitigate unwanted
toxicity, before this exciting novel technology could be largely
implemented in clinical practice.
To this end, a sophisticated genome editing tool consisting
of RNA-guided DNA endonucleases such as Cas9 and CRISPR
(clustered regularly interspaced short palindromic repeats) was
recently introduced to the scientific community. This versatile
tool, in contrast to its “predecessors” RNAi/genome delivery
systems, allows suppression (knock out) and/or overexpression
(knock in) of a target’s expression by introducing a double-
stranded break on the site of interest within the genome, which
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TABLE 5 | FDA-approved oligonucleotide therapies.
Brand name
[Generic name]
Type of
treatment
Target Disease Year of
approval
Relevant studies
Vitravene
[Fomivirsen]
ASO mRNA encoding IE2 CMV retinitis 1998 The Vitravene Study Group,
2002
Macugen,
[Pegaptanib]
Aptamer VEGF165 AMD of the retina 2004 Gragoudas et al., 2004
Kynamro
[Mipomersen]
ASO ApoB-100 mRNA Homozygous familial hypercholesterolemia 2013 Raal et al., 2010; McGowan
et al., 2012; Stein et al., 2012;
Thomas et al., 2013
Exondys 51
[Eteplirsen]
SSO DMD 001-gene (exon 51 target site) Duchenne muscular dystrophy 2016 Mendell et al., 2013
Spinraza
[Nusinersen]
ASO SMN2 mRNA Type 1, 2, and 3 spinal muscular atrophy 2016 Finkel et al., 2017
ASO, antisense oligonucelotides; IE2, immediate early region 2; CMV, cytomegalovirus; VEGF, vascular endothelial growth factor; AMD, age-related macular degeneration; ApoB-100,
apolipoprotein B-100; SSO, splice-switching oligo; DMD, Duchenne muscular dystrophy; SMN, survival motor neuron.
is guided upon RNA oligonucleotides, of 20–21 nt length,
complementary to genomic regions of the targeted segment
(Cong et al., 2013; Mali et al., 2013). Given that the cellular
machinery relies on two known mechanisms by which repairs
double-stranded nicks; the non-homologous end joining, which
bridges the two newly formed ends, and the homology-directed
repair, which utilizes a neighboring template to replace the
affected area through homologous recombination; the latter may
be exploited in order to introduce site-specific mutations in
the genome, supporting further the versatility of this method.
Importantly, this system empowers the simultaneous targeting
of multiple sites by simply providing more than one different
RNA guides that are directed toward different genomic regions
later subjected to Cas9 “nicking.” Since the endonuclease, Cas9,
is not endogenously expressed in human or mice systems,
but only in bacteria, like Streptococcus pyogenes (Sp) from
which has been originally isolated (Sapranauskas et al., 2011;
Jinek et al., 2012), a forced expression of Cas9 to the studied
system is a prerequisite that also features a common laboratory
practice hurdle when it comes to transfection-resistant systems,
e.g primary cells and thus the delivery strategy of Cas9 shall be
extensively considered in advance and tailored accordingly. This
innovative technology has already been employed to “correct”
disease contexts like Duchenne muscular dystrophy (Long et al.,
2016) hereditary tyrosynemia type I (Yin et al., 2016) and lethal
metabolic liver disease (Yang Y. et al., 2016) in animal models.
However, despite these promising outcomes there are several
limitations regarding the CRISPR–Cas9 system that have to
be acknowledged: (a) off-target activity resulting in unwanted
mutations, (b) low efficiency of genome editing using homology-
directed repair (HDR) and (c) challenging delivery of CRISPR–
Cas9 components into desired tissues using both viral and non-
viral methods (Long et al., 2016; Tycko et al., 2016; Komor
et al., 2017). Of particular interest, similar strategies have been
developed for rendering feasible the editing of the transcriptome
(Abudayyeh et al., 2016) instead of the genome. We, and others,
have previously underpinned the importance of adenosine (A)-
to-inosine (I) RNA editing, a widespread RNA modification
(Stellos et al., 2016) in human transcriptome, in RNAmetabolism
thusmodulating the context of several diseases (Choudhury et al.,
2012; Chen et al., 2013; Yamashita et al., 2013; Shoshan et al.,
2015) including atherosclerotic heart disease (Stellos et al., 2016),
as we have rigorously reviewed (Gatsiou et al., 2017). Recently,
a breakthrough proof-of-principle study, documented that the
use of Cas system in conjunction with the catalytic activity of
an A-to-I RNA editing enzyme, namely ADAR2, is able to edit
and correct disease-relevant mutations of full-length transcripts,
previously introduced into immortalized human cells (Cox et al.,
2017). In a different approach, another group fused the catalytic
domain of ADAR2 with an RNA binding domain directed to a
specific stem loop sequence embedded within the RNA guide,
restoring in this way the function of a neurodevelopmental
disorder-associated protein in primary neurons (Sinnamon et al.,
2017). Whether these concepts can be adopted first in animal
models at a preclinical stage manipulating endogenous A-to-I
RNA editing within specific transcripts, of which A-to-I RNA
editing levels have been previously linked with a particular
disease context, in order to attenuate the progression of a
disease remains yet to be investigated. Nevertheless, these “trail
blazer” findings provide convincing argumentation prompting us
to contemplate that genome and mainly transcriptome editing
feature as dynamic new additions to the “quiver” of RNA
therapeutics landmarking the dawn of a new era in RNA
therapeutics (Stellos, 2017a).
Without doubt, we are heading toward the new era of
precision medicine based on the discipline of an evidence-based
approach customized to patient-specific unique characteristics
(MacRae et al., 2016). Precision medicine is gaining ground over
the traditional “one-size-fits-all” medical treatment approach
(Houser, 2016; MacRae and Seidman, 2017) by enabling the
identification of the exact underlying molecular mechanism
of the disease and the design of therapeutic interventions
deployed specifically for this mechanism (Benjamin et al.,
2017). A bold, innovative research effort is now emerging
based on the fundamental concept of individualized treatment
taking into account individual variability in genes, environment
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and lifestyle (PMI Working Group report to the Advisory
Committee to the Director, NIH, 20151) in order to identify
which prevention strategy and treatment is effective in each
patient (MacRae et al., 2016; Shah et al., 2016). Advances in
precision medicine will soon be applicable in cardiology and
medicine.
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